JP2016501522A - 抗酸化栄養補助食品と、それに関連する方法 - Google Patents
抗酸化栄養補助食品と、それに関連する方法 Download PDFInfo
- Publication number
- JP2016501522A JP2016501522A JP2015544164A JP2015544164A JP2016501522A JP 2016501522 A JP2016501522 A JP 2016501522A JP 2015544164 A JP2015544164 A JP 2015544164A JP 2015544164 A JP2015544164 A JP 2015544164A JP 2016501522 A JP2016501522 A JP 2016501522A
- Authority
- JP
- Japan
- Prior art keywords
- blend
- quercetin
- turmeric
- rosemary
- supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 19
- 239000003963 antioxidant agent Substances 0.000 title abstract description 15
- 230000003078 antioxidant effect Effects 0.000 title abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 151
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 138
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 73
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 73
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 69
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 69
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 69
- 235000005875 quercetin Nutrition 0.000 claims abstract description 69
- 229960001285 quercetin Drugs 0.000 claims abstract description 69
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 68
- 235000013976 turmeric Nutrition 0.000 claims abstract description 68
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 65
- 239000013589 supplement Substances 0.000 claims abstract description 49
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 41
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 40
- 244000195452 Wasabia japonica Species 0.000 claims abstract description 40
- 235000000760 Wasabia japonica Nutrition 0.000 claims abstract description 40
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 39
- 230000004044 response Effects 0.000 claims abstract description 38
- 235000004072 Ocimum sanctum Nutrition 0.000 claims abstract description 35
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 claims abstract description 21
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 18
- 210000002700 urine Anatomy 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 241000282412 Homo Species 0.000 claims description 11
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 claims description 10
- 102000016938 Catalase Human genes 0.000 claims description 9
- 108010053835 Catalase Proteins 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 6
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000002485 urinary effect Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 235000006486 human diet Nutrition 0.000 claims description 5
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 4
- 240000003291 Armoracia rusticana Species 0.000 claims description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 244000136948 Ocimum sanctum Species 0.000 claims 11
- 210000005260 human cell Anatomy 0.000 claims 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 abstract description 36
- 108010018924 Heme Oxygenase-1 Proteins 0.000 abstract description 28
- 102000002737 Heme Oxygenase-1 Human genes 0.000 abstract description 25
- 240000002837 Ocimum tenuiflorum Species 0.000 abstract description 24
- 239000004615 ingredient Substances 0.000 abstract description 19
- 235000006708 antioxidants Nutrition 0.000 abstract description 13
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 230000037361 pathway Effects 0.000 abstract description 6
- 235000010676 Ocimum basilicum Nutrition 0.000 abstract description 3
- 241001529734 Ocimum Species 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 32
- 239000000523 sample Substances 0.000 description 25
- 238000003556 assay Methods 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 230000036542 oxidative stress Effects 0.000 description 15
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000002195 synergetic effect Effects 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 229910021642 ultra pure water Inorganic materials 0.000 description 10
- 239000012498 ultrapure water Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000090 biomarker Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 239000012086 standard solution Substances 0.000 description 8
- 235000012754 curcumin Nutrition 0.000 description 7
- 229940109262 curcumin Drugs 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 150000002535 isoprostanes Chemical class 0.000 description 6
- 241000894007 species Species 0.000 description 6
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 6
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 5
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 3
- 244000308180 Brassica oleracea var. italica Species 0.000 description 3
- 241000219193 Brassicaceae Species 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- -1 oxygen radical Chemical class 0.000 description 3
- 235000015487 sulforaphane Nutrition 0.000 description 3
- 229960005559 sulforaphane Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000219198 Brassica Species 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000002805 secondary assay Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- PJYONPGZTHDDJM-UHFFFAOYSA-N 2-amino-3-methyl-4h-imidazol-5-one;hydron;chloride Chemical compound Cl.CN1CC(=O)N=C1N PJYONPGZTHDDJM-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 244000178920 Brassica alboglabra Species 0.000 description 1
- 235000011303 Brassica alboglabra Nutrition 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 241001332183 Brassica oleracea var. sabauda Species 0.000 description 1
- 235000004214 Brassica oleracea var. sabauda Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589157 Rhizobiales Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 101100451295 Takifugu rubripes hmox gene Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 235000020984 low fruit intake Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940013224 niacin / niacinamide Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002997 prostaglandinlike Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000001366 vegetable intake Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
植物をベースとした異なる4種類のブレンド(ブレンドA、B、C、D)をそれぞれ2通りの用量(300mgと600mg)で調製した。研究に参加する健康な男性を60人集めた。参加者は、ランダムに4つの群に分け、4種類のブレンドそれぞれに15人の参加者を割り当てた。ブレンドAとブレンドBを消費することを選択した参加者群からの結果は、この明細書の中でのちに議論する。ブレンドCとブレンドDを消費することを選択した参加者群からの結果は、本発明とは関係がない。なぜならブレンドCとブレンドDは、ブレンドAとブレンドBとは異なる材料のブレンドを含んでいるからである。
患者から回収したサンプルで検出されたバイオマーカー/遺伝子発現レベルの差をベースライン測定値から計算した。ベースラインから、低用量補助食品を14日間消費した後に得られたサンプルへの変化を“L-BL”で表わす。低用量相の後に採取したサンプルから、高用量補助食品を14日間消費した後に採取したサンプルへの検出値の差は、“H-L”で表わす。A群に関しては、14日間の期間にわたる高用量消費の後のサンプルと、高用量補助食品にビタミンとミネラルと色ブレンドの組み合わせを14日間の期間続けた後のサンプルの差を求めることによって測定した別のデルタが存在している。このデルタを“C-H”で表わす。
Claims (20)
- ターメリックと、
ケルセチンと、
ローズマリーを含有する栄養補助食品であって、
前記ターメリックとケルセチンとローズマリーがこの補助食品の中に1:3:5の比率で存在し、
この補助食品が被験対象に投与されたとき、前記ターメリックとケルセチンとローズマリーが協働して、AREを刺激することとHMOX-1の発現を誘導することの少なくとも一方を実現する栄養補助食品。 - 前記ターメリックとケルセチンとローズマリーが、それぞれ33mg、100mg、167mgの量で中に存在している、請求項1に記載の栄養補助食品。
- 前記ターメリックとケルセチンとローズマリーが、それぞれ66mg、200mg、333mgの量で中に存在している、請求項1に記載の栄養補助食品。
- ビタミンとミネラルの少なくとも一方を含む、請求項1に記載の栄養補助食品。
- 栄養補助食品に含めるためのブレンドであって、このブレンドは、ターメリックとケルセチンとローズマリーからなり、そのターメリックとケルセチンとローズマリーが、それぞれ、前記補助食品が被験対象に投与されたとき、AREを刺激することとHMOX-1の発現を誘導することの少なくとも一方に十分な量かつ比率で前記補助食品の中に存在するブレンド。
- 前記ターメリックとケルセチンとローズマリーが、1:3:5の比率で前記補助食品の中に存在している、請求項5に記載のブレンド。
- 前記ターメリックとケルセチンとローズマリーが、ARE DNA配列5’-GTGACTCAGCA-3’を含むベクターをステーブルトランスフェクトしたヒト肝細胞中において、前記ターメリックとケルセチンとローズマリーの個別の任意の1つの応答の約2〜4倍の応答でAREを刺激するのに十分な比率で存在する、請求項5に記載のブレンド。
- 前記ターメリックとケルセチンとローズマリーが、ヒトの尿中の8-イソプロスタンのレベルと血清中のカタラーゼのレベルの一方を低下させるのに十分な比率で存在する、請求項5に記載のブレンド。
- 前記ターメリックとケルセチンとローズマリーが、ヒトにおいてグルタチオンペルオキシダーゼとスーパーオキシドディスムターゼの一方の産生を増やすのに十分な比率で存在する、請求項5に記載のブレンド。
- ヒトの食事を補助する方法であって、
ターメリックとケルセチンとローズマリーが1:3:5の比率で存在するように含まれた栄養補助食品を用意し、
その栄養補助食品をヒトに経口投与することで、そのヒトでAREを刺激することと、そのヒトの細胞でHMOX-1の発現を誘導することの一方を実現する操作を含有する方法。 - 前記ターメリックとケルセチンとローズマリーが、前記被験対象に経口投与するためのカプセル、錠剤、液体形態のうちの少なくとも1つに含まれている、請求項8に記載の方法。
- ホーリー・バジルと、
ワサビと、
ブロッコリ種子エキスを含有する栄養補助食品であって、
前記ホーリー・バジルとワサビとブロッコリ種子エキスが、この補助食品の中に1:1:0.2の比率で存在し、
この補助食品が被験対象に投与されたとき、前記ホーリー・バジルとワサビとブロッコリ種子エキスが、キノンレダクターゼの産生を刺激し、HMOX-1の発現を誘導する栄養補助食品。 - 前記ホーリー・バジルとワサビとブロッコリ種子エキスが、それぞれ136mg、136mg、28mgの量で中に存在している、請求項12に記載の栄養補助食品。
- 前記ホーリー・バジルとワサビとブロッコリ種子エキスが、それぞれ273mg、273mg、54mgの量で中に存在している、請求項12に記載の栄養補助食品。
- 栄養補助食品に含めるためのブレンドであって、このブレンドは、ホーリー・バジルとワサビとブロッコリ種子エキスからなり、そのホーリー・バジルとワサビとブロッコリ種子エキスが、前記補助食品が被験対象に投与されたとき、キノンレダクターゼ活性を刺激することとHMOX-1の発現を誘導することの少なくとも一方に十分な量かつ比率で前記補助食品の中に存在するブレンド。
- 前記ホーリー・バジルとワサビとブロッコリ種子エキスが、前記補助食品の中に1:1:0.2の比率で存在している、請求項15に記載のブレンド。
- 前記ホーリー・バジルとワサビとブロッコリ種子エキスが、ヒトで尿中の8-イソプロスタンのレベルを低下させるのに十分な比率で存在している、請求項15に記載のブレンド。
- 前記ホーリー・バジルとワサビとブロッコリ種子エキスが、ヒトでスーパーオキシドディスムターゼを増やすのに十分な比率で存在している、請求項15に記載のブレンド。
- ヒトの食事を補助する方法であって、
ホーリー・バジルとワサビとブロッコリ種子エキスが1:1:0.2の比率で存在するように含まれた栄養補助食品を用意し;
この栄養補助食品をヒトに経口投与し、そのヒトの細胞中でキノンレダクターゼ活性を刺激することとHMOX-1の発現を誘導することの少なくとも一方を実現する操作を含有する方法。 - 前記ホーリー・バジルとワサビとブロッコリ種子エキスが、前記被験対象に経口投与するためのカプセル、錠剤、液体形態のうちの少なくとも1つに含まれる、請求項15に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018234453A JP6930957B2 (ja) | 2012-11-26 | 2018-12-14 | 抗酸化栄養補助食品と、それに関連する方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261729919P | 2012-11-26 | 2012-11-26 | |
US61/729,919 | 2012-11-26 | ||
PCT/US2013/071597 WO2014082027A2 (en) | 2012-11-26 | 2013-11-25 | Antioxidant dietary supplement and related method |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018234453A Division JP6930957B2 (ja) | 2012-11-26 | 2018-12-14 | 抗酸化栄養補助食品と、それに関連する方法 |
JP2020141127A Division JP2021000099A (ja) | 2012-11-26 | 2020-08-24 | 抗酸化栄養補助食品と、それに関連する方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016501522A true JP2016501522A (ja) | 2016-01-21 |
JP2016501522A5 JP2016501522A5 (ja) | 2017-01-12 |
JP6825809B2 JP6825809B2 (ja) | 2021-02-10 |
Family
ID=49759587
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015544164A Active JP6825809B2 (ja) | 2012-11-26 | 2013-11-25 | 抗酸化栄養補助食品と、それに関連する方法 |
JP2018234453A Active JP6930957B2 (ja) | 2012-11-26 | 2018-12-14 | 抗酸化栄養補助食品と、それに関連する方法 |
JP2020141127A Pending JP2021000099A (ja) | 2012-11-26 | 2020-08-24 | 抗酸化栄養補助食品と、それに関連する方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018234453A Active JP6930957B2 (ja) | 2012-11-26 | 2018-12-14 | 抗酸化栄養補助食品と、それに関連する方法 |
JP2020141127A Pending JP2021000099A (ja) | 2012-11-26 | 2020-08-24 | 抗酸化栄養補助食品と、それに関連する方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9517249B2 (ja) |
JP (3) | JP6825809B2 (ja) |
KR (2) | KR20200128438A (ja) |
CN (1) | CN104797144B (ja) |
HK (1) | HK1208309A1 (ja) |
TW (2) | TWI660680B (ja) |
WO (1) | WO2014082027A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI660680B (zh) * | 2012-11-26 | 2019-06-01 | 美商通路實業集團國際公司 | 抗氧化膳食增補劑及其相關方法 |
CA2904865A1 (en) * | 2013-03-15 | 2014-10-16 | Nutramax Laboratories, Inc. | Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions |
ES2689105B8 (es) * | 2018-04-30 | 2019-05-28 | Monteloeder S L | Composición de extractos vegetales con flavonoides para paliar los múltiples efectos de la contaminación del aire sobre la piel |
US11938152B2 (en) | 2020-08-06 | 2024-03-26 | Kedar N Prasad | High-dose antioxidants in cancer treatment |
CN115300580A (zh) | 2022-04-25 | 2022-11-08 | 捷通国际有限公司 | 用于抑制晚期糖化终产物的组合物和方法 |
CN115462419B (zh) * | 2022-09-20 | 2023-11-24 | 湖北海顺达食品科技有限公司 | 一种调味辣椒鸡油及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US6352712B1 (en) * | 1999-04-30 | 2002-03-05 | Daniel O. Lukaczer | Dietary supplements for treating fatigue-related syndromes |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4163803A (en) | 1978-07-19 | 1979-08-07 | Goldscher Kenneth J | Turmeric coloring process and composition for foods and beverages |
US5077069A (en) | 1991-01-07 | 1991-12-31 | Kabi Pharmacia Ab | Composition of natural antioxidants for the stabilization of polyunsaturated oils |
IT1244647B (it) | 1991-02-05 | 1994-08-08 | Salvatore Mancuso | Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo. |
AU703958B2 (en) | 1995-05-05 | 1999-04-01 | Hauser Inc. | High purity carnosic acid from rosemary and sage extracts by PH-controlled precipitation |
US6086910A (en) | 1997-09-19 | 2000-07-11 | The Howard Foundation | Food supplements |
US5897865A (en) | 1997-06-30 | 1999-04-27 | Nguyen; Van Bich | Turmeric for treating skin disorders |
US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
US5989558A (en) | 1997-12-05 | 1999-11-23 | Lopes; Carlos Alberto Correia | Method of using rosmarinus officinalis for treating various diseases |
DE19809304A1 (de) | 1998-03-05 | 1999-09-09 | Merck Patent Gmbh | Formulierungen mit antiviraler Wirkung |
CA2367387C (en) | 1999-03-16 | 2009-06-23 | Herwig Buchholz | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
US6534086B1 (en) | 2000-03-06 | 2003-03-18 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
US6309675B1 (en) | 1999-07-21 | 2001-10-30 | Nancy Laning Sobczak | Therapeutic composition including plantain and aloe vera for treatment of arthritis and other afflictions |
FI20000004A0 (fi) | 2000-01-03 | 2000-01-03 | Slk Foundation | Flavonoidilääke... |
US6399089B1 (en) | 2000-05-15 | 2002-06-04 | A. Glenn Braswell | Compositions and methods for regulating metabolism and balancing body weight |
US7128933B2 (en) | 2000-09-01 | 2006-10-31 | Mitchell Kurk | Composition and method for the treatment of personal odors |
US6733797B1 (en) | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
US20030190381A1 (en) | 2001-02-02 | 2003-10-09 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
ES2317990T3 (es) | 2001-02-09 | 2009-05-01 | New Chapter, Inc. | Composicion y metodo para detoxificacion de humo. |
US6387416B1 (en) | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
US6592896B2 (en) | 2001-08-06 | 2003-07-15 | The Quigley Corporation | Medicinal composition and method of using it |
ES2274842T3 (es) | 2001-08-18 | 2007-06-01 | Cognis Ip Management Gmbh | Mezclas de principios activos. |
US7279185B2 (en) | 2001-10-26 | 2007-10-09 | Metaproteonics, Llc | Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
US8143062B2 (en) * | 2001-11-30 | 2012-03-27 | Hirsch Alan R | Method and composition for enhancing weight loss |
US6488957B1 (en) * | 2001-12-17 | 2002-12-03 | Teddy A. Koumarianos | Food additive composition |
US20030157205A1 (en) | 2001-12-31 | 2003-08-21 | Jensen Claude Jarakae | Inhibitory and preventative effects of processed morinda citrifolia on mutagenesis and carcinogenesis in mammals |
KR20040089733A (ko) | 2002-03-12 | 2004-10-21 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 쿠미눔 시미눔 및 이의 추출물 및 분획물의생체이용률/생체내효능 증진 활성 |
JP2005532394A (ja) | 2002-07-02 | 2005-10-27 | ガリレオ ファーマシューティカルズ, インコーポレイティド | 雌性被験体における炎症性症状および/またはバイオマーカーの低減のための組成物および方法 |
AU2003251300A1 (en) | 2003-05-16 | 2005-01-21 | Mitchell Kurk | Composition and method for the treatment of personal odors |
WO2005000331A2 (en) | 2003-06-04 | 2005-01-06 | Mucosal Therapeutics, Inc. | Compositions for the treatment and prevention of degenerative joint disorders |
WO2005082407A1 (en) | 2003-11-03 | 2005-09-09 | Musc Foundation For Research Development | Use of quercetin and resveratrol to treat and prevent oral cancer |
WO2005077393A1 (en) | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Herbal formulation comprising extracts of adhatoda, hedychium and curcuma as cough syrup |
EP2266586A1 (en) | 2004-03-23 | 2010-12-29 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
US20050244522A1 (en) | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
GB0411166D0 (en) | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
TWI342780B (en) * | 2004-08-11 | 2011-06-01 | Access Business Group Int Llc | Dietary supplement |
US7622142B2 (en) * | 2004-09-14 | 2009-11-24 | New Chapter Inc. | Methods for treating glioblastoma with herbal compositions |
GB2423928B (en) | 2004-11-16 | 2008-04-09 | Efflux Technology Inc | Methods and compositions for treating pain |
US20060110468A1 (en) | 2004-11-24 | 2006-05-25 | Liang Liu | Herbal formulations for arthritis |
WO2006067796A1 (en) | 2004-12-24 | 2006-06-29 | Council Of Scientific And Industrial Research | Herbal formulation as memory enhacher in alzheimer condition |
US7429397B2 (en) | 2004-12-28 | 2008-09-30 | Council Of Scientific And Industrial Research | Herbal formulation as memory enhancer in Alzheimer condition |
US20060141072A1 (en) | 2004-12-29 | 2006-06-29 | Arvanitidou Evangelia S | Oxidation resistant dentifrice compositions |
WO2006079109A2 (en) | 2005-01-21 | 2006-07-27 | Rdx Technologies, Inc. | Non-toxic antimicrobial compositions and methods using pro-oxidative polyphenols and antioxidants |
US7883728B2 (en) | 2005-05-30 | 2011-02-08 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
KR100749941B1 (ko) * | 2005-08-22 | 2007-08-21 | 롯데쇼핑주식회사 | 고추냉이 추출물을 포함하는 간암 예방용 조성물과 건강 식품 |
US8962058B2 (en) | 2005-11-23 | 2015-02-24 | The Coca-Cola Company | High-potency sweetener composition with antioxidant and compositions sweetened therewith |
MY161865A (en) | 2006-02-10 | 2017-05-15 | Mannatech Inc | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
US9192644B2 (en) | 2006-03-06 | 2015-11-24 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders |
CN101095668B (zh) | 2006-06-29 | 2010-09-08 | 山东绿叶天然药物研究开发有限公司 | 迷迭香酸在制备治疗或预防肝纤维化和肾纤维化的药物中的应用 |
US20080031940A1 (en) | 2006-08-02 | 2008-02-07 | Al Rodriguez | Quercetin-containing composition, methods of making, and methods of using |
US20080031980A1 (en) | 2006-08-02 | 2008-02-07 | Al Rodriguez | Curcumin-containing composition, methods of making, and methods of using |
US20080045475A1 (en) | 2006-08-20 | 2008-02-21 | Phillip Edward Littmann | Elemental cellular therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and homeostatic processes |
WO2008023387A2 (en) | 2006-08-23 | 2008-02-28 | Century Biologicals Private Limited | Water formulation with herbal hint and a process therefor |
US20080095757A1 (en) | 2006-10-23 | 2008-04-24 | Now Health Group, Inc. | Vitamin c compositions |
EP1925311A1 (en) | 2006-11-15 | 2008-05-28 | Melbrosin International Produktions und Vertriebs GmbH & Co KG | Use of a plant extract or plant juice |
US20080181937A1 (en) | 2007-01-29 | 2008-07-31 | Majid Fotuhi | Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard) |
WO2008120220A1 (en) | 2007-04-03 | 2008-10-09 | Ganga Raju Gokaraju | Synergistic anti-inflammatory and antioxidant dietary supplement compositions |
US7794758B2 (en) | 2007-04-05 | 2010-09-14 | Pmc Formulas, Inc. | Compounds and methods for promoting cellular health and treatment of cancer |
WO2008143182A1 (ja) | 2007-05-17 | 2008-11-27 | Kaneka Corporation | 甘草ポリフェノールを含有する組成物 |
CA2701031A1 (en) | 2007-10-01 | 2009-04-09 | Colgate-Palmolive Company | Oral compositions containing botanical extracts |
EP2205255B8 (en) | 2007-10-03 | 2015-09-30 | Sabell Corporation | Herbal compositions and methods for treating hepatic disorders |
EP2231150A4 (en) | 2008-01-18 | 2011-06-22 | Thomas Christian Lines | METHOD FOR SEARCH TREATMENT WITH CROSS-COMPOSITE COMPOSITIONS |
CN101356974B (zh) | 2008-06-10 | 2012-05-30 | 黎秋萍 | 能捕获消除自由基的生物保健食品 |
US8680053B2 (en) | 2008-07-09 | 2014-03-25 | Quercegen Pharmaceuticals Llc | Improving renal function with quercetin-containing compositions |
US20100179103A1 (en) | 2008-07-21 | 2010-07-15 | Ketan Desai | Curcumin cyclodextrin combination for preventing or treating various diseases |
WO2010056318A2 (en) | 2008-11-12 | 2010-05-20 | Andrew Loblaw | Nutritional supplement |
JP5778584B2 (ja) | 2009-01-19 | 2015-09-16 | ライコード・リミテツド | カロテノイドとポリフェノールとの相乗的組み合わせ |
JP5764288B2 (ja) | 2009-09-24 | 2015-08-19 | ハウス食品グループ本社株式会社 | ウコン抽出物とガジュツ抽出物とを含有する組成物 |
US9011936B2 (en) | 2009-10-16 | 2015-04-21 | Naturex, S.A. | Extract of Rosmarinus officinalis L. leaves for pharmaceutical applications |
JP2013508352A (ja) | 2009-10-19 | 2013-03-07 | ライラ ニュートラシューティカルズ | アセトゲニンを含む抽出物、フラクションおよび組成物ならびにそれらの応用 |
CA2774054A1 (en) | 2009-11-06 | 2011-05-12 | Alcon Research, Ltd. | Nutritional supplements for relief of dry eye |
WO2011060305A1 (en) | 2009-11-12 | 2011-05-19 | Nox Technologies, Inc. | Potato skin compositions that lower cytosolic nadh level to mimic calorie restriction |
BR112012013193A2 (pt) | 2009-12-04 | 2016-03-01 | Colgate Palmolive Co | composição oral contendo zizyphus joazeiro e métodos relacionados |
WO2011116220A2 (en) | 2010-03-17 | 2011-09-22 | Arbonne International Llc | Oral supplement |
BR112012025488B1 (pt) | 2010-04-09 | 2020-12-29 | Unilever N.V | composição de cuidados orais e uso de uma fonte de íons de zinco |
US20110305779A1 (en) | 2010-06-10 | 2011-12-15 | Cowan Fred M | Phytochemical combinations that regulate pathological immunity |
US20120052126A1 (en) | 2010-08-30 | 2012-03-01 | Yashwant Pathak | Nanoemulsions Containing Antioxidants And Other Health-Promoting Compounds |
US20120207862A1 (en) | 2010-09-02 | 2012-08-16 | Morre D James | ORAL INHIBITORS OF AGE-RELATED NADH OXIDASE (arNOX), COMPOSITIONS AND NATURAL SOURCES |
WO2012035480A2 (en) | 2010-09-15 | 2012-03-22 | Cadila Pharmaceuticals Limited | Pharmaceutical compositions of curcumin |
US9415035B2 (en) | 2010-09-17 | 2016-08-16 | Maine Natural Health Company, Inc. | Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof |
US20130203701A1 (en) | 2010-09-17 | 2013-08-08 | Maine Natural Health, Inc. | Compositions containing omega-3 oil and uses thereof |
WO2012050895A1 (en) | 2010-09-28 | 2012-04-19 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
ES2511145T3 (es) | 2010-10-14 | 2014-10-22 | Abbott Gmbh & Co. Kg | Formulación de dispersión sólida de curcuminoides |
US8709509B2 (en) | 2011-02-17 | 2014-04-29 | Suresh Balkrishna Patankar | Herbal composition for the treatment of wound healing, a regenerative medicine |
JP6625792B2 (ja) | 2011-03-14 | 2019-12-25 | エヌエスイー プロダクツ インコーポレイテッド | 細胞浄化を促進するための経口製剤 |
US20120237590A1 (en) | 2011-03-16 | 2012-09-20 | Signpath Pharma Inc. | Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control |
WO2013016257A1 (en) | 2011-07-25 | 2013-01-31 | Us Cosmeceu Techs Llc | Botanical antioxidant compositions and methods of preparation and use thereof |
ITTO20110901A1 (it) | 2011-10-10 | 2013-04-11 | Medestea Biotech S P A | Composizione sinergica per la prevenzione ed il trattamento di disturbi connessi all'invecchiamento |
US10391096B2 (en) | 2011-10-13 | 2019-08-27 | Quercegen Pharmaceuticals Llc | Method for treating thrombotic disorders using quercetin-containing compositions |
WO2013090715A1 (en) | 2011-12-15 | 2013-06-20 | Metaproteomics, Llc | Phytonutrient compositions and methods to protect against radical mediated cellular and dna damage |
TWI660680B (zh) | 2012-11-26 | 2019-06-01 | 美商通路實業集團國際公司 | 抗氧化膳食增補劑及其相關方法 |
-
2013
- 2013-11-25 TW TW102142795A patent/TWI660680B/zh active
- 2013-11-25 US US14/088,765 patent/US9517249B2/en active Active
- 2013-11-25 JP JP2015544164A patent/JP6825809B2/ja active Active
- 2013-11-25 KR KR1020207031076A patent/KR20200128438A/ko not_active Application Discontinuation
- 2013-11-25 CN CN201380061555.0A patent/CN104797144B/zh active Active
- 2013-11-25 KR KR1020157013277A patent/KR102173501B1/ko active IP Right Grant
- 2013-11-25 WO PCT/US2013/071597 patent/WO2014082027A2/en active Application Filing
- 2013-11-25 TW TW107138812A patent/TWI671014B/zh active
-
2015
- 2015-09-16 HK HK15109039.7A patent/HK1208309A1/xx unknown
-
2016
- 2016-11-03 US US15/342,627 patent/US10201583B2/en active Active
-
2018
- 2018-11-30 US US16/205,762 patent/US20190083566A1/en not_active Abandoned
- 2018-12-14 JP JP2018234453A patent/JP6930957B2/ja active Active
-
2020
- 2020-08-24 JP JP2020141127A patent/JP2021000099A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
US6210701B1 (en) * | 1999-04-30 | 2001-04-03 | Healthcomm International, Inc. | Medical food for treating inflammation-related diseases |
US6352712B1 (en) * | 1999-04-30 | 2002-03-05 | Daniel O. Lukaczer | Dietary supplements for treating fatigue-related syndromes |
US6602517B2 (en) * | 1999-04-30 | 2003-08-05 | Metagenics, Inc. | Dietary supplements for treating inflammation-related diseases |
Non-Patent Citations (1)
Title |
---|
MOLECULES, vol. 15, JPN6017036277, 2010, pages 7792 - 7814, ISSN: 0003645828 * |
Also Published As
Publication number | Publication date |
---|---|
CN104797144B (zh) | 2017-10-20 |
HK1208309A1 (en) | 2016-03-04 |
US20140147526A1 (en) | 2014-05-29 |
US9517249B2 (en) | 2016-12-13 |
JP2019068825A (ja) | 2019-05-09 |
KR20200128438A (ko) | 2020-11-12 |
CN104797144A (zh) | 2015-07-22 |
TWI660680B (zh) | 2019-06-01 |
TW201440668A (zh) | 2014-11-01 |
JP2021000099A (ja) | 2021-01-07 |
TWI671014B (zh) | 2019-09-11 |
US20190083566A1 (en) | 2019-03-21 |
KR102173501B1 (ko) | 2020-11-04 |
TW201906539A (zh) | 2019-02-16 |
WO2014082027A3 (en) | 2014-08-28 |
JP6825809B2 (ja) | 2021-02-10 |
JP6930957B2 (ja) | 2021-09-01 |
KR20150089009A (ko) | 2015-08-04 |
US20170106041A1 (en) | 2017-04-20 |
US10201583B2 (en) | 2019-02-12 |
WO2014082027A2 (en) | 2014-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6930957B2 (ja) | 抗酸化栄養補助食品と、それに関連する方法 | |
JP6903594B2 (ja) | 食品、栄養補助食品、化粧品および医薬品に有用な複数の相乗的抗酸化活性を示すフィトコンプレックス | |
JP2018530517A (ja) | 一酸化窒素レベルを急激に上昇させるための組成物および方法 | |
WO2012122295A2 (en) | Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin | |
Hoenjet et al. | Effect of a nutritional supplement containing vitamin E, selenium, vitamin C and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study | |
Kim et al. | Anti-inflammatory activity of Chrysanthemum zawadskii var. latilobum leaf extract through haem oxygenase-1 induction | |
Grant et al. | Diet’s role in modifying risk of Alzheimer’s disease: History and present understanding | |
Singh et al. | Effects of fenugreek seeds on cardiovascular diseases and other chronic diseases | |
Cordova et al. | Perfecting the plate: adding cardioprotective compounds to the diet | |
Misbahuddin et al. | Effectiveness of garlic oil in the treatment of arsenical palmar keratosis | |
Ferguson et al. | Effect of a polyphenol-rich dietary supplement containing Pinus massoniana bark extract on blood pressure in healthy adults: A parallel, randomized placebo-controlled trial | |
EP3761973B1 (en) | Natural combination products and methods for regulation of kidney and excretory system function | |
Sultan et al. | Drug–nutrient interactions in the elderly | |
Raja et al. | In vivo antioxidant activity of Limnophila heterophylla and Michelia champaca | |
Tsalamandris et al. | Anti-oxidant treatment | |
Wong et al. | Nutritional Impact on the Nitric Oxide Pathway | |
Granta et al. | Handbook of Intervention and Alzheimer's Disease, CA Raji et al.(Eds.) 113 IOS Press, 2024 O 2024 IOS Press. All rights reserved. | |
Moyad | Heart Healthy= Prostate Healthy and SAM are the Ideal “Natural” Recommendations for Prostate Cancer | |
RU2360669C1 (ru) | Способ нутритивной профилактики и лечения атеросклероза | |
Murad et al. | COMPARATIVE CHARACTERIZATION OF ANTIOXIDANT PROFILE OF VITAMIN-E AND RED DATES IN PLACEBO AND TESTED GROUPS OF HYPERLIPIDEMIC PATIENTS | |
Costello et al. | Dietary supplements: current knowledge and future frontiers | |
Guo | Effects of Total Polyphenol Intakes on Cardiovascular Disease Risk Factors in an Elderly Population at High Cardiovascular Risk | |
Giovane et al. | Protective effects of food on cardiovascular diseases | |
Yance | Cholesterol, Statins and the Truth about Cardiovascular Health and Disease | |
Costello et al. | Dietary Supplements for Health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161122 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170926 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181214 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20181214 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20190108 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190212 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190219 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190426 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190514 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20190528 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200225 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200407 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200824 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20201110 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20201215 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20201215 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6825809 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |